Historical record - last NADAC effective date: 4/19/2023
Product Information
OXYMORPHONE HCL 5 MG TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.5201 per EA under NDC 00054028325. Its NADAC has been published 542 times since Nov 28, 2013.
FDA first approved this application on Sep 27, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054028325
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
4/19/2023
Active Ingredients
OXYMORPHONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090964FDA Approved
9/27/2010
TE Code
AB
On Market Since
9/27/2010
Pharmacological Classes
Price Statistics
The NADAC for OXYMORPHONE HCL 5 MG TABLET has been published 542 times since Nov 28, 2013, and over the history we have for it it has declined 74.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5201 per EA |
|---|---|
| All-time high | $2.1959 (Jan 15, 2014) |
| All-time low | $0.3420 (Sep 23, 2020) |
| Median price | $0.9216 |
| Average price | $1.0244 |
| Largest weekly change | +123.9% (Dec 23, 2020) |
| Weeks tracked | 542 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
0.0%
5Y
+38.3%
All
-74.6%
Last surveyed Apr 10, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the oxymorphone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
oxymorphone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYMORPHONE HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYMORPHONE HCL 5 MG TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $0.5201 per EA (NDC 00054028325), effective Apr 10, 2024.
How has the price of OXYMORPHONE HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYMORPHONE HCL 5 MG TABLET has declined 74.6%. It has been tracked across 542 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for OXYMORPHONE HCL 5 MG TABLET?
Since Nov 28, 2013, the NADAC for OXYMORPHONE HCL 5 MG TABLET has ranged from a low of $0.3420 (Sep 23, 2020) to a high of $2.1959 (Jan 15, 2014), with a median of $0.9216 per EA.
Are there cheaper alternatives to OXYMORPHONE HCL 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of OXYMORPHONE HCL 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OXYMORPHONE HCL 5 MG TABLET?
OXYMORPHONE HCL 5 MG TABLET (NDC 00054028325) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.